The Food and Drug Administration Modernization Act of 1997 amended the standard of approval for effectiveness by providing that under certain circumstances, one adequate and well-controlled clinical investigation and confirmatory evidence would be sufficient. The standard of effectiveness has been a point of contention throughout the modern history of drug development and remains so today. With the imminent need to consider the reauthorization of the Prescription Drug User Fee Act, the implementation of the Food and Drug Administration Modernization Act of 1997 will also be open to discussion. In anticipation of the upcoming Congressional and public debate surrounding these laws, the Tufts Center for the Study of Drug Development conducted a survey of nearly 50 of the leading pharmaceutical and biotechnology firms in order to assess the level and manner of utilization of the single controlled trial at the outset of the Food and Drug Administration Modernization Act of 1997 to serve as a frame of reference for these discussions.
Kulynych J. Will FDA relinquish the “gold standard” for new drug approval? Redefining “substantial evidence” in the FDA Modernization Act of 1997. Food Drug Law J. 1999;54(1):127–149.
Mathieu M. New Drug Development: A Regulatory Overview. Revised 5th edition. Waltham, MA: Pa-rexel;2000.
US Food and Drug Administration. Statement Regarding the Demonstration of Effectiveness of Human Drug Products and Devices. Rockville, MD: US Food and Drug Administration; August 1, 1995.
Food and Drug Administration Modernization Act of 1997. Pub Law 105–115 (1997 Nov 21); 21 USC 355a; 111 Stat. 2296.
House Report 105–310, to accompany H.R. 1411. Prescription Drug Modernization Act of 1997. October 7, 1997. 105th Congress, 1st Session.
PDUFA III could move through Congress in 2001, Rep. Burr suggests. Pink Sheet. 2001 May 7;63(19):3–4.
US Food and Drug Administration. Guidance for Industry: Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products. Rock-ville, MD: US Food and Drug Administration; May 1998.
Clinical development times for new drugs drop 18%, reversing 12-yr trend. Impact Report. Boston, MA: Tufts Center for the Study of Drug Development; July 1999.
Temple R. Experiences with single trials leading to Section 115 of FDAMA and May 1998 evidence document. Presented at “The Use of the Single, Adequate and Well-controlled Efficacy Trial (SCT) to Support Approval,” Washington DC, January 22–23, 2001.
New paradigms for clinical development of biologic products. Biotechnology Law Report. August 1999; 328(4):18.
Cocchetto DM, Jones DR. Faster access to drugs for serious or life-threatening illnesses through the use of the accelerated approval regulation in the United States. Drug Inf J. 1998;32(1):27–35.
Botstein P. One controlled clinical trial for a new use, route, formulation, or population. Presented at “The Use of the Single, Adequate and Well-controlled Efficacy Trial (SCT) to Support Approval,” Washington DC, January 22–23, 2001.
European Medicines Evaluation Agency. Points to consider on application with I. Meta-analyses; 2. One pivotal study (draft). Committee for Proprietary Medicinal Products (CPMP), European Agency for the Evaluation of Medicinal Products. London: European Medicines Evaluation Agency, May 31, 2001.
FDA Backgrounder: The FDA Modernization Act of 1997. Nov. 21,1997. http://www.fda.gov/opacom/backgrounders/modact.htm.
Weiss KD. DIA conference on the use of the SCT to support approval. Presented at “The Use of the Single, Adequate and Well-controlled Efficacy Trial (SCT) to Support Approval,” Washington DC, January 22–23, 2001.
About this article
Cite this article
Milne, CP. The Single Controlled Trial: Industry Survey Indicates that Implementation is Still a Work in Progress. Ther Innov Regul Sci 36, 291–302 (2002). https://doi.org/10.1177/009286150203600207
- Single controlled trial
- Food and Drug Administration Modernization Act of 1997